Alzinova AB (publ) (ALZ.ST)
- Previous Close
2.1800 - Open
2.1700 - Bid 2.0200 x --
- Ask 2.0500 x --
- Day's Range
1.9860 - 2.2000 - 52 Week Range
0.9493 - 4.6200 - Volume
497,668 - Avg. Volume
301,002 - Market Cap (intraday)
182.789M - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.47
Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer's disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in Mölndal, Sweden.
www.alzinova.comRecent News: ALZ.ST
View MorePerformance Overview: ALZ.ST
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALZ.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALZ.ST
View MoreValuation Measures
Market Cap
194.38M
Enterprise Value
173.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.48k
Price/Book (mrq)
1.57
Enterprise Value/Revenue
5.77k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-122.26%
Return on Assets (ttm)
-9.94%
Return on Equity (ttm)
-17.29%
Revenue (ttm)
16.81M
Net Income Avi to Common (ttm)
-20.55M
Diluted EPS (ttm)
-0.3100
Balance Sheet and Cash Flow
Total Cash (mrq)
15.5M
Total Debt/Equity (mrq)
0.65%
Levered Free Cash Flow (ttm)
-29.38M